Literature DB >> 29038647

Extrahepatic Benefits Achieved With Sustained Virologic Response in Patients With Hepatitis C Virus Infection.

Marcelo Kugelmas1.   

Abstract

Entities:  

Year:  2017        PMID： 29038647      PMCID： PMC5635432     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.

Authors:  Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer
Journal:  Gut       Date:  2017-06-20       Impact factor: 23.059

2.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Authors:  Thierry Poynard; John McHutchison; Michael Manns; Christian Trepo; Karen Lindsay; Zachary Goodman; Mei-Hsiu Ling; Janice Albrecht
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

3.  Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.

Authors:  Zobair M Younossi; Maria Stepanova; Fatema Nader; Ira M Jacobson; Ed Gane; David Nelson; Eric Lawitz; Sharon L Hunt
Journal:  Hepatology       Date:  2014-04-30       Impact factor: 17.425

Review 4.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

Review 5.  Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.

Authors:  Z Younossi; L Henry
Journal:  Aliment Pharmacol Ther       Date:  2015-01-23       Impact factor: 8.171

6.  The impact of hepatitis C burden: an evidence-based approach.

Authors:  Z M Younossi; F Kanwal; S Saab; K A Brown; H B El-Serag; W R Kim; A Ahmed; M Kugelmas; S C Gordon
Journal:  Aliment Pharmacol Ther       Date:  2014-01-26       Impact factor: 8.171
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.